Medincell: Participation Terms in the Combined General Meeting
2024年8月21日 - 12:47AM
ビジネスワイヤ(英語)
Regulatory News:
The Annual General Meeting and Extraordinary General Meeting
will be held at Medincell's (Paris:MEDCL) headquarters (3 rue des
Frères Lumière, 34830 Jacou, France) on Thursday, September 12,
2024, at 6.00 pm, CEST.
All shareholders of the company are invited to attend the
meeting or to follow it live (French only) on the company’s website
via the link www.medincell.com/fr/live-fr/
The secure remote voting system via the Votaccess platform will
be open from Thursday, August 22, 2024, at 10:00 am to Wednesday,
September 11, 2024, at 3:00 pm, CEST.
Medincell will hold a video conference (French only) on
Wednesday, September 4, 2024, at 6 pm to present the resolutions of
the Annual General Meeting and answer questions from
shareholders.
Connection link: www.medincell.com/fr/live-fr/
Terms and conditions of
participation
Medincell strongly encourages all its shareholders to exercise
their voting rights, either by remote voting, which must be cast
before the General Meeting, or during the General Meeting for
shareholders present in person.
Medincell shareholders who wish to vote by remotely may do so
before the General Meeting as follows:
- Internet voting will be available and should be used as a
priority: the secure voting platform Votaccess will be open from
Thursday, August 22, 2024, at 10 am to Wednesday, September 11,
2024, at 3 pm, Paris time. Shareholders will be able to vote by
Internet or give their proxy to the Chairman of the Meeting until
the day before the General Meeting (i.e., Wednesday, September 11,
2024) at 3 pm, Paris time.
- Shareholders may also vote by post following the procedures set
out in the notice of meeting published in the Bulletin des Annonces
Légales et Obligatoires on August 5th, 2024. The deadline for
receipt of forms is September 9, 2024.
All shareholders may send their written questions, either by
registered letter with a return receipt requested addressed to the
Chairman of the Board at the company’s registered office (3 rue des
Frères Lumière, 34830 Jacou) or by e-mail to legal@medincell.com,
no later than the fourth business day preceding the date of the
Shareholders’ Meeting (i.e., September 6, 2024). A certificate of
account registration must accompany the questions.
As the company cannot control the identity of the persons
attending the meeting remotely, only the persons physically present
will be able to ask questions during the General Meeting.
Availability of documents relating to
the General Meeting
The notice of meeting, valid as notice of convocation, which
includes the agenda, draft resolutions, and the main terms of
participation and voting at the Shareholders' Meeting, was
published in the Bulletin des Annonces Légales et Obligatoires N°.
94 of August 5th, 2024.
The preparatory documents and information relating to this
General Meeting will be made available to shareholders under the
legal and regulatory conditions and will be available on the
website:
https://www.medincell.com/general-meeting/
Shareholders are invited to consult the section dedicated to the
General Meeting on the Company's website:
https://www.medincell.com/general-meeting/
About Medincell
Medincell is a clinical- and commercial-stage biopharmaceutical
licensing company developing long-acting injectable drugs in many
therapeutic areas. Our innovative treatments aim to guarantee
compliance with medical prescriptions, to improve the effectiveness
and accessibility of medicines, and to reduce their environmental
footprint. They combine active pharmaceutical ingredients with our
proprietary BEPO® technology which controls the delivery of a drug
at a therapeutic level for several days, weeks or months from the
subcutaneous or local injection of a simple deposit of a few
millimeters, entirely bioresorbable. The first treatment based on
BEPO® technology, intended for the treatment of schizophrenia, was
approved by the FDA in April 2023, and is now distributed in the
United States by Teva under the name UZEDY® (BEPO® technology is
licensed to Teva under the name SteadyTeq™). We collaborate with
leading pharmaceutical companies and foundations to improve global
health through new treatment options. Based in Montpellier,
Medincell currently employs more than 140 people representing more
than 25 different nationalities.
UZEDY® and SteadyTeq™ are registered trademarks of Teva
Pharmaceuticals.
www.medincell.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240820976438/en/
David Heuzé - Head of Corporate and Financial Communications,
and ESG david.heuze@medincell.com / +33 (0)6 83 25 21 86
Grace Kim - Head of US Financial Strategy and IR
grace.kim@medincell.com / +1 (646) 991-4023
Investors Relations France Louis-Victor
Delouvrier/Alban Dufumier medincell@newcap.eu / +33 (0)1 44 71
94 94
Media Relations Nicolas Mérigeau
medincell@newcap.eu / +33 (0)1 44 71 94 94
Medincell (EU:MEDCL)
過去 株価チャート
から 9 2024 まで 10 2024
Medincell (EU:MEDCL)
過去 株価チャート
から 10 2023 まで 10 2024